Page 169 - Haematologica Vol. 110 - January 2025

ARTICLE - Targeted CDK7 and BRD4 inhibition in myeloma
targeting CDK7 in combination with epigenetic therapies relying on BRD4 inhibition for the treatment of patients with MM and WM.
Disclosures
NCM is a consultant for BMS, Janssen, Oncopep, Amgen, Karyopharm, Legened, AbbVie, Takeda and GSK and serves on the board of directors of, and holds stocks options in, Oncopep. The other authors have no conflicts of interest.
Contributions
MF designed and conducted the study and wrote the man- uscript. YY performed the in vitro and in vivo experiments and analyzed the data. SD, JFN, MY, CC and VJW helped with the in vitro and in vivo experiments. NM provided crit- ical evaluation of experimental data and the manuscript.
References
1. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303.
2. Fulciniti M, Martinez-Lopez J, Senapedis W, et al. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017;129(16):2233-2245.
3. Li N, Lopez MA, Linares M, et al. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA- damaging agents in Waldenstrom macroglobulinemia. Clin Cancer Res. 2019;25(1):369-377.
4. Ng YLD, Ramberger E, Bohl SR, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13(1):1009.
5. de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, et al. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer. 2023;4(5):754-773.
6. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214-231.
7. Fujisawa T, Filippakopoulos P. Functions of bromodomain- containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246-262.
8. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337-356.
9. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
10. Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123(5):697-705.
11. Stubbs MC, Burn TC, Sparks R, et al. The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin Cancer Res. 2019;25(1):300-311.
12. Zhang X, Lee HC, Shirazi F, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif
Y. Yao et al. We would like to thank Christina Usher for her comments
on the manuscript.
Funding
This study was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) P01 grant (CA155258- 10) to MF and National Natural Science Foundation of China (81870163) and Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Insti- tutions (19KJA560001) to YY.
Data-sharing statement
The data that support the findings of this study are available on request from the corresponding author.
family proteins are active against pre-clinical models of
multiple myeloma. Leukemia. 2018;32(10):2224-2239.
13. Amorim S, Stathis A, Gleeson M, et al. Bromodomain inhibitor
OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196-204.
14. Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2020;11:621093.
15. Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8(1):24-36.
16. Fulciniti M, Lin CY, Samur MK, et al. Non-overlapping control of transcriptome by promoter- and super-enhancer-associated dependencies in multiple myeloma. Cell Rep. 2018;25(13):3693-3705.e6.
17. Yao Y, Ng JF, Park WD, et al. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023;141(23):2841-2852.
18. Wang Y, Manokaran C, Wu S, Roberts TM. The Mediator captures CDK7, an attractive transcriptional target in cancer. Cancer Cell. 2021;39(9):1184-1186.
19. Olson CM, Liang Y, Leggett A, et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol. 2019;26(6):792-803.e10.
20. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82(12):3712-3720.
21. Hideshima T, Mitsiades C, Ikeda H, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010;115(18):3772-3775.
22. Feng M, Xu H, Zhou W, Pan Y. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023;42(1):44.
23. Gao Y, Volegova M, Nasholm N, et al. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma. Front Oncol. 2022;11:773186.
24. Zhang W, Ge H, Jiang Y, et al. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer
Acknowledgments
Haematologica | 110 January 2025
161